Cite
Baldi BG, Radzikowska E, Cottin V, et al. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021;doi: 10.1016/j.chest.2021.12.640.
Baldi, B. G., Radzikowska, E., Cottin, V., Dilling, D. F., Ataya, A., Ribeiro Carvalho, C. R., Harari, S., Koslow, M., Grutters, J. C., Inoue, Y., Gupta, N., & Johnson, S. R. (2021). COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest, . https://doi.org/10.1016/j.chest.2021.12.640
Baldi, Bruno Guedes, et al. "COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition." Chest vol. (2021). doi: https://doi.org/10.1016/j.chest.2021.12.640
Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Ribeiro Carvalho CR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. Chest. 2021 Dec 20; doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 20. PMID: 34942174; PMCID: PMC8687712.
Copy
Download .nbib